MARKET WIRETradingView • 1d ago
Anbio Biotechnology Estimates – NASDAQ:NNNNTradingView report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
Why NNNN Stock surged +4.46% Today — RQD Quant Desk Flash
$3.51 +4.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.53
Anbio Biotechnology (Class A) (NNNN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $505.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NNNN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.51 (+4.46% 1D, market cap $505.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NNNN ranks #592 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NNNN compare to MYGN and TKNO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D- (35/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $559.6M) and TKNO (Alpha Teknova Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $432.5M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NNNN?
▼
Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.53 (+0.61%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY NNNN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 87.2% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.57+4.2% Next Q
43
Q2 (-2Q)Grade D$3.72+3.2% Next Q
40
Q3 (-1Q)Grade E$3.84-8.6% Next Q
38
CurrentGrade D-$3.51-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NNNN Turnaround Squeeze
While NNNN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.23) and Max Pain ($3.69) forces dealer call-delta covering toward $46.97.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NNNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NNNN Stock surged +4.46% Today — RQD Quant Desk Flash
Anbio Biotechnology (Class A) (NNNN) surged +4.46% to $3.51, trading at 2% of its 52-week range ($3.09 – $44.73). Stretched risk/reward at 84x P/E (17% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3.09 – $44.73) with RSI-14 at 36.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.51 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 87.2% gross margin and $0 annual free cash flow.
Live NNNN Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session - SCWorx (NASDAQ:WORX), Myriad Genetics (NASDABenzinga report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Femasys Inc. (FEMY) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 2d ago
Anbio Biotechnology (NNNN) Climbs 3.50% to $3.84 as Buyers Test Upper Range - NHNL Ratiohttps://www.siam.in/ report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
Synsam AB (publ) (SYNSAM.ST) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHChartMill • 14d ago
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's SessionTop gainers rose as much as 55.88% and top losers fell as much as 53.13% in today's session, led by PRSO, BRZE, CJMB, and SXTC.
MARKET WIREBenzinga • 14d ago
12 Health Care Stocks Moving In Tuesday's Intraday SessionGainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNNN)
- ✓Walkthrough of NNNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NNNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -87.98%🛡️ HOLDING TREND SUPPORT
2026-11-04O $3.36H $3.51L $3.36C $3.51VOL 56.5K
RES: $7.27SUP: $1.79SMA50: $5.23SMA200: $16.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NNNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth
vs. +5.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NNNN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NNNN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NNNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNNN)
Health Care Rank #592 of 1015
⚔️ MYGN vs NNNN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NNNN vs. MYGN, TKNO, ACHV, QDEL)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Anbio Biotechnology (Class A) (NNNN) ranks #592 by composite RQD confidence (35/100, grade D-) and #433 by equity capitalization ($505.1M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NNNN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NNNN
ACTIVE
Anbio Biotechnology (Class A) | D- | 35/100 | 83.6x | 87.2% | 17.0% | +4.46% | $505.1M | Benchmark Subject |
| MYGN Myriad Genetics Inc. | D | 47/100 | — | 69.9% | -35.0% | -7.87% | $559.6M | /mygn-vs-nnnn → |
| TKNO Alpha Teknova Inc. | D- | 42/100 | — | 33.2% | -21.3% | -4.75% | $432.5M | /tkno-vs-nnnn → |
| ACHV Achieve Life Sciences Inc. | D- | 39/100 | — | — | -35.0% | -3.22% | $680.2M | /achv-vs-nnnn → |
| QDEL QuidelOrtho Corporation | E | 21/100 | — | — | -35.0% | +5.89% | $962.1M | /qdel-vs-nnnn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001982708 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported GAAP revenue of $8.6M (+5.6% vs. FY2024 revenue of $8.2M , and +28.8% cumulative change since FY2023) , GAAP net income of $6.4M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (-423.9% YoY). On the balance sheet, NNNN closed FY2025 with $30.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $8.6M | $6.4M | -$6.7M | -$6.7M | $30.2M | — |
| FY2024 (FY) | 2024-12-31 | $8.2M | $2.4M | $2.1M | $2.1M | $18.9M | — |
| FY2023 (FY) | 2023-12-31 | $6.7M | $2.3M | $898.4K | $898.4K | — | — |
3. NNNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $3.51 (+4.46% 1D, market cap $505.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NNNN ranks #592 in composite RQD confidence.
How does NNNN compare to MYGN and TKNO in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D- (35/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, MYGN (Myriad Genetics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $559.6M) and TKNO (Alpha Teknova Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -21.3%, cap $432.5M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NNNN?
Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NNNN trading relative to its 50-day, 200-day, and 52-week technical levels?
NNNN last traded at $3.51 (+4.46% on volume of 56,470 shares), positioning the stock -32.89% below its 50-day simple moving average ($5.23) and -79.22% below its 200-day simple moving average ($16.89). Across its 52-week range of $3.09 to $44.73, NNNN sits at the 1.0% percentile with a 14-day RSI of 36.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.07 to $3.95).
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ SEC XBRL & RQD VERIFIED
NNNN — Anbio Biotechnology (Class A): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Anbio Biotechnology (Class A) (NNNN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.51 (+4.46% 1D, market capitalization $505.1M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 17.0%, gross margin of 87.2%, operating margin of 66.7%, and free cash flow yield of -1.26%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Anbio Biotechnology (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile does not describe its specific products, customers, or revenue model. Per the market data, the company reports a gross margin of 87.2%, an operating margin of 66.7%, and a net margin of 68%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported $8.6M in annual revenue (up from $8.2M in FY2024, +5.6% YoY) and $6.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.7M revenue, $2.3M net income) through FY2025, NNNN scaled operating cash flow to -$6.7M and free cash flow to -$6.7M, backed by $30.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.26% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.09 – $44.73 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 83.6x trailing P/E and 91.5x EV/EBITDA against 66.7% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The sector classification (Health Care) and industry classification (In Vitro & In Vivo Diagnostic Substances) are the only available context for ripple analysis.
- Key Question #1: Can NNNN sustain or expand its 66.7% operating margin and 17.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $8.6M and free cash flow of -$6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NNNN's 77.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NNNN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Anbio Biotechnology (Class A) (NNNN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Anbio Biotechnology Estimates – NASDAQ:NNNN TradingView report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session - SCWorx (NASDAQ:WORX), Myriad Genetics (NASDA Benzinga report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Femasys Inc. (FEMY) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 2d ago
Anbio Biotechnology (NNNN) Climbs 3.50% to $3.84 as Buyers Test Upper Range - NHNL Ratio https://www.siam.in/ report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
Synsam AB (publ) (SYNSAM.ST) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Anbio Biotechnology (Class A) (NNNN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH ChartMill • 14d ago
Top Movers: Gainers Rise 55.88%, Losers Fall 53.13% in Today's Session Top gainers rose as much as 55.88% and top losers fell as much as 53.13% in today's session, led by PRSO, BRZE, CJMB, and SXTC.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NNNN Bull vs. Bear Conversation Board — What's Your Call at $3.51?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NNNN 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $4.03 (+19.9%)
📌 Pinned Debate Reported FY 2025 net income of $6.4M and a 66.7% operating margin show strong profitability, supported by a 17% ROIC.
Long NNNN at $3.36 targeting $4.03. Reported FY 2025 net income of $6.4M and a 66.7% operating margin show strong profitability, supported by a 17% ROIC.. Institutional whale score is 3/20 and the risk/reward vs. the $3.09 52-week low is skewed heavily in favor of bulls.
ArenaChamp_24 🐂 BULL
@MultipleCompression Fair point on 83.6x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: In Vitro & In Vivo Diagnostic Substances. If gross margin (87.2%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $2.89 (-14.0%)
Spot @ $3.36 Negative FCF of -$6.7M in FY 2025 and a P/E (TTM) of 83.6 leave the price resting on earnings the cash flows do not yet confirm.
Fading this rally in NNNN at $3.36. Negative FCF of -$6.7M in FY 2025 and a P/E (TTM) of 83.6 leave the price resting on earnings the cash flows do not yet confirm.. With a beta of 1.0 and the stock sitting at $3.36 (52-wk range $3.09–$44.73), the easy multiple expansion is already priced in.